← Back to Session

Time Completed: 00:00:05

Final Score 0%

0
180

Questions

  • Q1. Skipped
  • Q2. Skipped
  • Q3. Skipped
  • Q4. Skipped
  • Q5. Skipped
  • Q6. Skipped
  • Q7. Skipped
  • Q8. Skipped
  • Q9. Skipped
  • Q10. Skipped
  • Q11. Skipped
  • Q12. Skipped
  • Q13. Skipped
  • Q14. Skipped
  • Q15. Skipped
  • Q16. Skipped
  • Q17. Skipped
  • Q18. Skipped
  • Q19. Skipped
  • Q20. Skipped
  • Q21. Skipped
  • Q22. Skipped
  • Q23. Skipped
  • Q24. Skipped
  • Q25. Skipped
  • Q26. Skipped
  • Q27. Skipped
  • Q28. Skipped
  • Q29. Skipped
  • Q30. Skipped
  • Q31. Skipped
  • Q32. Skipped
  • Q33. Skipped
  • Q34. Skipped
  • Q35. Skipped
  • Q36. Skipped
  • Q37. Skipped
  • Q38. Skipped
  • Q39. Skipped
  • Q40. Skipped
  • Q41. Skipped
  • Q42. Skipped
  • Q43. Skipped
  • Q44. Skipped
  • Q45. Skipped
  • Q46. Skipped
  • Q47. Skipped
  • Q48. Skipped
  • Q49. Skipped
  • Q50. Skipped
  • Q51. Skipped
  • Q52. Skipped
  • Q53. Skipped
  • Q54. Skipped
  • Q55. Skipped
  • Q56. Skipped
  • Q57. Skipped
  • Q58. Skipped
  • Q59. Skipped
  • Q60. Skipped
  • Q61. Skipped
  • Q62. Skipped
  • Q63. Skipped
  • Q64. Skipped
  • Q65. Skipped
  • Q66. Skipped
  • Q67. Skipped
  • Q68. Skipped
  • Q69. Skipped
  • Q70. Skipped
  • Q71. Skipped
  • Q72. Skipped
  • Q73. Skipped
  • Q74. Skipped
  • Q75. Skipped
  • Q76. Skipped
  • Q77. Skipped
  • Q78. Skipped
  • Q79. Skipped
  • Q80. Skipped
  • Q81. Skipped
  • Q82. Skipped
  • Q83. Skipped
  • Q84. Skipped
  • Q85. Skipped
  • Q86. Skipped
  • Q87. Skipped
  • Q88. Skipped
  • Q89. Skipped
  • Q90. Skipped
  • Q91. Skipped
  • Q92. Skipped
  • Q93. Skipped
  • Q94. Skipped
  • Q95. Skipped
  • Q96. Skipped
  • Q97. Skipped
  • Q98. Skipped
  • Q99. Skipped
  • Q100. Skipped
  • Q101. Skipped
  • Q102. Skipped
  • Q103. Skipped
  • Q104. Skipped
  • Q105. Skipped
  • Q106. Skipped
  • Q107. Skipped
  • Q108. Skipped
  • Q109. Skipped
  • Q110. Skipped
  • Q111. Skipped
  • Q112. Skipped
  • Q113. Skipped
  • Q114. Skipped
  • Q115. Skipped
  • Q116. Skipped
  • Q117. Skipped
  • Q118. Skipped
  • Q119. Skipped
  • Q120. Skipped
  • Q121. Skipped
  • Q122. Skipped
  • Q123. Skipped
  • Q124. Skipped
  • Q125. Skipped
  • Q126. Skipped
  • Q127. Skipped
  • Q128. Skipped
  • Q129. Skipped
  • Q130. Skipped
  • Q131. Skipped
  • Q132. Skipped
  • Q133. Skipped
  • Q134. Skipped
  • Q135. Skipped
  • Q136. Skipped
  • Q137. Skipped
  • Q138. Skipped
  • Q139. Skipped
  • Q140. Skipped
  • Q141. Skipped
  • Q142. Skipped
  • Q143. Skipped
  • Q144. Skipped
  • Q145. Skipped
  • Q146. Skipped
  • Q147. Skipped
  • Q148. Skipped
  • Q149. Skipped
  • Q150. Skipped
  • Q151. Skipped
  • Q152. Skipped
  • Q153. Skipped
  • Q154. Skipped
  • Q155. Skipped
  • Q156. Skipped
  • Q157. Skipped
  • Q158. Skipped
  • Q159. Skipped
  • Q160. Skipped
  • Q161. Skipped
  • Q162. Skipped
  • Q163. Skipped
  • Q164. Skipped
  • Q165. Skipped
  • Q166. Skipped
  • Q167. Skipped
  • Q168. Skipped
  • Q169. Skipped
  • Q170. Skipped
  • Q171. Skipped
  • Q172. Skipped
  • Q173. Skipped
  • Q174. Skipped
  • Q175. Skipped
  • Q176. Skipped
  • Q177. Skipped
  • Q178. Skipped
  • Q179. Skipped
  • Q180. Skipped

Pathology

Haematology

Question 60 of 180

A 75 year old female presents to ED with right arm pain. X-ray shows lytic bone lesions and you suspect multiple myeloma. Overproduction of which type of immunoglobulin is most commonly associated with this condition:

Answer:

The paraprotein is IgG in 60% of cases, IgA in 20% and light chain only in almost all the rest.

Multiple Myeloma

Multiple myeloma is a neoplastic disease characterised by plasma cell accumulation in bone marrow, the presence of monoclonal protein in the serum and/or urine and, in symptomatic patients, related tissue damage.

Incidence

98% of cases of myeloma occur over the age of 40 years with a peak incidence between 65 and 70 years. The disease is twice as common in black individuals compared to those of white or Asian origin.

Clinical Features

A useful acronym for tissue damage in myeloma is CRAB:

  • Hypercalcaemia
  • Renal impairment (proteinaceous deposits from light chain proteinuria, hypercalcaemia, uric acid, amyloid and pyelonephritis may all contribute to renal failure)
  • Anaemia
  • Bone pain (especially backache, resulting from vertebral collapse and pathological fractures)

Other features include:

  • Amyloidosis (features include macroglossia, carpal tunnel syndrome, diarrhoea)
  • Hyperviscosity syndrome (features include purpura, haemorrhages, visual disturbance, CNS symptoms, neuropathies and heart failure)
  • Recurrent infections (related to deficient antibody production, abnormal cell-mediated immunity and neutropaenia)
  • Abnormal bleeding tendency (resulting from paraprotein interfering with platelet function and coagulation factors and from thrombocytopaenia in advanced disease)
  • Peripheral neuropathy
  • Deep vein thrombosis

Laboratory Findings

  • Presence of a paraprotein in serum/urine (the paraprotein is IgG in 60% of cases, IgA in 20% and light chain only in almost all the rest)
  • Elevated serum immunoglobulin-free light chains (κ or λ light chain proteins, synthesised by plasma cells, that have not been paired with heavy chains; they are normally made in small quantities and filtered from the serum into the kidney but they are produced by almost all malignant plasma cells and so the serum free light chain assay is useful in diagnosis and monitoring of myeloma
  • Bence-Jones protein (free light chains) in urine
  • Reduced serum IgG, IgA and IgM levels (immunoparesis)
  • Normochromic normocytic or macrocytic anaemia
  • Marked Rouleaux formation on blood film
  • Neutropaenia and thrombocytopaenia in advanced disease
  • High ESR
  • Increased plasma cells in the bone marrow (usually more than 20%), often with abnormal forms
  • Hypercalcaemia (45% of patients)
  • Elevated creatinine (20% of cases)
  • Low serum albumin in advanced disease
  • Osteolytic lesions (60% of patients), osteoporosis (20% of patients) or pathological fractures/vertebral collapse on radiological investigation
  • Raised serum β2-microglobulin (useful indicator of prognosis)

Management

The life expectancy of patients with myeloma has improved markedly in recent years with the introduction of new drugs such as proteasome inhibitors and immunomodulatory agents. The major initial treatment decision is between the use of intensive combination chemotherapy (mostly for patients aged less than 70 years old) or non-intensive therapy for older patients.

Prognosis

The outlook for patients with myeloma is improving markedly. The overall median survival is now 7-10 years and in younger (less than 50 years) patients it can be over 10 years.

Report A Problem

Is there something wrong with this question? Let us know and we’ll fix it as soon as possible.

Loading Form...

Close
  • Biochemistry
  • Blood Gases
  • Haematology
Biochemistry Normal Value
Sodium 135 – 145 mmol/l
Potassium 3.0 – 4.5 mmol/l
Urea 2.5 – 7.5 mmol/l
Glucose 3.5 – 5.0 mmol/l
Creatinine 35 – 135 μmol/l
Alanine Aminotransferase (ALT) 5 – 35 U/l
Gamma-glutamyl Transferase (GGT) < 65 U/l
Alkaline Phosphatase (ALP) 30 – 135 U/l
Aspartate Aminotransferase (AST) < 40 U/l
Total Protein 60 – 80 g/l
Albumin 35 – 50 g/l
Globulin 2.4 – 3.5 g/dl
Amylase < 70 U/l
Total Bilirubin 3 – 17 μmol/l
Calcium 2.1 – 2.5 mmol/l
Chloride 95 – 105 mmol/l
Phosphate 0.8 – 1.4 mmol/l
Haematology Normal Value
Haemoglobin 11.5 – 16.6 g/dl
White Blood Cells 4.0 – 11.0 x 109/l
Platelets 150 – 450 x 109/l
MCV 80 – 96 fl
MCHC 32 – 36 g/dl
Neutrophils 2.0 – 7.5 x 109/l
Lymphocytes 1.5 – 4.0 x 109/l
Monocytes 0.3 – 1.0 x 109/l
Eosinophils 0.1 – 0.5 x 109/l
Basophils < 0.2 x 109/l
Reticulocytes < 2%
Haematocrit 0.35 – 0.49
Red Cell Distribution Width 11 – 15%
Blood Gases Normal Value
pH 7.35 – 7.45
pO2 11 – 14 kPa
pCO2 4.5 – 6.0 kPa
Base Excess -2 – +2 mmol/l
Bicarbonate 24 – 30 mmol/l
Lactate < 2 mmol/l

Join our Newsletter

Stay updated with free revision resources and exclusive discounts

©2017 - 2024 MRCEM Success